Background: The world is still witnessing a largely ongoing spread of COVID-19, therefore, the scientific findings in this area need to be shared promptly.
Objectives: We aimed to assess the usefulness of Atorvastatin treatment in the reduction of COVID-19 mortality in patients with or without Diabetes Mellitus (DM) and to correlate them with C - reactive protein (CRP) levels.
Methods: Patients with pneumonia symptoms, positive lung CT scan, and confirmed SARS-CoV-2 on RT-PCR were consecutively enrolled in this study. Outcome was defined as intensive care unit admission and death. Clinical data and history of atorvastatin administration were evaluated. CRP levels were measured at baseline and repeated after one week in all patients.
Results: A total of 200 patients were included. Their mean age was 60.5 (SD= 16.5) years, 113 (56.5%) patients were male, 47 (23.5%) with pre-existing diabetes, and 64 (32%) patients were taking atorvastatin routinely. Of all the studied patients, 68 (34%) required ICU admission. No gender differences were found in ICU admission and death. The baseline CRP was not significantly different but the secondary CRP was significantly different between DM and non- DM groups. Secondary CRP also showed a significant reduction in patients who were receiving atorvastatin (p= 0.017). The mortality was the same either in atorvastatin or non-atorvastatin groups (p= 0.715).
Conclusions: It seems, taking statin has only some beneficial effects on the improvement of CRP levels in patients with COVID-19. To achieve a reliable result, clinical trials is recommended.